Compare British American Tobacco PLC (BTI) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
British American Tobacco PLC vs Neurocrine Biosciences Inc — how do they compare? British American Tobacco PLC trades at $58.71 (market cap $124.84B), while Neurocrine Biosciences Inc trades at $170.99 (market cap $17.30B). The key difference: British American Tobacco PLC is far larger — about 7.2× Neurocrine Biosciences Inc's market cap, and British American Tobacco PLC pays a 5.74% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| BTI | NBIX | |
|---|---|---|
Market Cap | $124.84B | $17.30B |
Sector | Consumer Staples | Health |
52-Week High | $66.70 | $180.55 |
52-Week Low | $50.39 | $123.10 |
Enterprise Value | $166.06B | $16.39B |
Dividend Yield | 5.74% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
British American Tobacco (BTI) trades at $58.95, down 1.78% on the day, with mixed technical signals showing bearish moving averages but neutral oscillators. Fundamentally, the company maintains strong profitability with 30.32% net income margin and attractive valuation at 12.79 P/E ratio. Recent earnings show beats in Q2 and Q4 2025, though Q4 2024 missed expectations. The company is undergoing restructuring with 5,500 job cuts announced in June 2026 to streamline operations and reduce costs.
BTI presents a compelling value opportunity with strong dividend yield and improving earnings trajectory, though facing regulatory headwinds and declining cigarette volumes. The stock's current valuation appears attractive relative to historical levels, supported by robust cash flow generation and strategic pivot toward smoke-free products. Key risks include ongoing regulatory pressures and consumer shift away from traditional tobacco products.
Neurocrine Biosciences (NBIX) trades at $174.10, down 1.7% on the day but maintains strong technical momentum with bullish moving averages and support at $173. The company demonstrates robust fundamentals with Q1 2026 revenue growth of 44% year-over-year to $811 million and consistent earnings beats, including Q1 2026 EPS of $1.94 versus $1.22 expected. Recent pipeline advancements include Phase 2 studies for crinecerfont and positive VYKAT XR data presented at ENDO 2026.
NBIX presents compelling growth prospects with analyst consensus price target of $195.75 (12% upside) and 86% buy ratings. Key opportunities include blockbuster drug performance and strategic acquisitions, while risks involve clinical trial outcomes and competitive pressures in neuroscience therapeutics. The stock's current valuation at 26.5x P/E reflects growth expectations but requires continued execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About British American Tobacco PLC
Following the acquisition of Reynolds American, British American Tobacco is neck-and-neck with Philip Morris International to be the largest listed global tobacco company--slightly larger than PMI on net revenue, but slightly smaller on total tobacco volume. British American's Global Drive Brands are Dunhill, Kent, Pall Mall, Lucky Strike, and Rothmans, and it also owns Newport and Camel in the U.S. The firm also sells vapor e-cigarettes, including its Vype brand, heated tobacco, with Glo, as well as roll- your-own and smokeless tobacco products. The company holds 31% of ITC Limited, the leading Indian cigarette-maker.
Read more on BTI →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
